Pfizer Inc. Share Price Today: Live Updates & Key Insights

Pfizer Inc. share price today is $26.86, up -1.61%. The stock opened at $27.11 against the previous close of $27.3, with an intraday high of $27.12 and low of $26.635.

Pfizer Inc. Share Price Chart

Pfizer Inc.

us-stock
To Invest in {{usstockname}}
us-stock

Pfizer Inc. Share Price Performance

$26.86 -0.0161(-1.61%) PFE at 13 Mar 2026 02:43 PM Drug Manufacturers - General
Lowest Today 26.635
Highest Today 27.12
Today’s Open 27.11
Prev. Close 27.3
52 Week High 27.94
52 Week Low 19.50
Day’s Range: Low 26.635 High 27.12
52-Week Range: Low 19.50 High 27.94
1 day return -
1 Week return -0.66
1 month return -2.57
3 month return +1.55
6 month return +12.01
1 year return +4.92
3 year return -32.59
5 year return -24.13
10 year return -

Pfizer Inc. Institutional Holdings

Vanguard Group Inc 9.52

BlackRock Inc 8.75

State Street Corp 5.26

Vanguard Total Stock Mkt Idx Inv 3.15

Vanguard 500 Index Investor 2.55

Geode Capital Management, LLC 2.27

Morgan Stanley - Brokerage Accounts 1.31

NORGES BANK 1.29

iShares Core S&P 500 ETF 1.27

Fidelity 500 Index 1.27

State Street® SPDR® S&P 500® ETF 1.19

Northern Trust Corp 1.13

JPMorgan Chase & Co 0.99

Massachusetts Financial Services Company 0.98

State Farm Mutual Automobile Ins Co 0.96

Vanguard Value Index Inv 0.92

Wellington Management Company LLP 0.92

Charles Schwab Investment Management Inc 0.89

Fisher Asset Management, LLC 0.87

Bank of America Corp 0.78

Legal & General Group PLC 0.75

State Street®HlthCrSelSectSPDR®ETF 0.74

Amundi 0.73

Royal Bank of Canada 0.69

Dimensional Fund Advisors, Inc. 0.64

Bank of New York Mellon Corp 0.61

UBS Asset Mgmt Americas Inc 0.60

Vanguard Institutional Index I 0.57

State St S&P 500® Indx SL Cl III 0.53

Vanguard Institutional 500 Index Trust 0.45

Vanguard High Dividend Yield ETF 0.40

Blackrock Eq Idx Fund CF 0.36

Vanguard Equity-Income Inv 0.35

Russell 1000 Index Fund 0.32

Blackrock Russ 1000 Eq Idx Composite 0.31

Vanguard Health Care ETF 0.30

Franklin Income A1 0.30

MFS Large Cap Value Equity 0.30

MFS Value A 0.29

iShares Select Dividend ETF 0.28

Pfizer Inc. Market Status

Strong Buy: 7

Buy: 2

Hold: 15

Sell: 0

Strong Sell: 1

Pfizer Inc. Fundamentals

Market Cap 155235.09 M

PB Ratio 1.7859

PE Ratio 19.927

Enterprise Value 205600.10 M

Total Assets 208160.00 M

Volume 38542832

Pfizer Inc. Company Financials

Annual Revenue FY25:62579000000 62579.0M, FY24:63627000000 63627.0M, FY23:58496000000 58496.0M, FY22:100330000000 100330.0M, FY21:81288000000 81288.0M

Annual Profit FY25:44014000000 44014.0M, FY24:45776000000 45776.0M, FY23:29283000000 29283.0M, FY22:65986000000 65986.0M, FY21:50467000000 50467.0M

Annual Net worth FY25:7770000000 7770.0M, FY24:8031000000 8031.0M, FY23:2119000000 2119.0M, FY22:31372000000 31372.0M, FY21:21979000000 21979.0M

Quarterly Revenue Q4/2025:17557000000 17557.0M, Q3/2025:16654000000 16654.0M, Q2/2025:14653000000 14653.0M, Q1/2025:13715000000 13715.0M, Q4/2024:17763000000 17763.0M

Quarterly Profit Q4/2025:12285000000 12285.0M, Q3/2025:12482000000 12482.0M, Q2/2025:9420000000 9420.0M, Q1/2025:9827000000 9827.0M, Q4/2024:11854000000 11854.0M

Quarterly Net worth Q4/2025:-1648000000 -1648.0M, Q3/2025:3541000000 3541.0M, Q2/2025:2910000000 2910.0M, Q1/2025:2967000000 2967.0M, Q4/2024:410000000 410.0M

About Pfizer Inc. & investment objective

Company Information Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Organisation Drug Manufacturers - General

Employees 75000

Industry Drug Manufacturers - General

CEO Dr. Albert Bourla D.V.M., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right